Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
22 11 2022
Historique:
accepted: 15 07 2022
received: 07 02 2022
pubmed: 18 8 2022
medline: 18 11 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

Early alterations within the bone marrow microenvironment that contribute to the progression of multiple myeloma (MM) from its precursor stages could be the key to identifying novel therapeutic approaches. However, the intrinsic variability in cellular populations between patients and the differences in sample processing and analysis methods have made it difficult to identify consistent changes between data sets. Here, we used single-cell RNA sequencing of bone marrow cells from precursor stages, monoclonal gammopathy of unknown significance, smoldering MM, and newly diagnosed MM and analyzed our data in combination with a previously published data set that used a similar patient population and sample processing. Despite the vast interpatient heterogeneity, some alterations were consistently observed in both data sets. We identified changes in immune cell populations as the disease progressed, which were characterized by a substantial decrease in memory and naïve CD4 T cells, and an increase in CD8+ effector T cells and T-regulatory cells. These alterations were further accompanied by an enrichment of nonclonal memory B cells and an increase in CD14 and CD16 monocytes in MM compared with its precursor stages. These results provide crucial information on the immune changes associated with the progression to clinical MM and can help to develop immune-based strategies for patient stratification and early therapeutic intervention.

Identifiants

pubmed: 35977111
pii: 486276
doi: 10.1182/bloodadvances.2022007217
pmc: PMC9647426
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5873-5883

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Auteurs

Carolina Schinke (C)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Alexandra M Poos (AM)

University of Heidelberg, Baden-Württemberg, Germany.
German Cancer Research Center, Heidelberg, Germany.

Michael Bauer (M)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Lukas John (L)

University of Heidelberg, Baden-Württemberg, Germany.
German Cancer Research Center, Heidelberg, Germany.

Sarah Johnson (S)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Shayu Deshpande (S)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Luis Carrillo (L)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Daisy Alapat (D)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Leo Rasche (L)

University of Würzburg, Würzburg, Germany.

Sharmilan Thanendrarajan (S)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Maurizio Zangari (M)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Samer Al Hadidi (S)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Frits van Rhee (F)

University of Arkansas for Medical Sciences, Myeloma Center, Little Rock, AR.

Faith Davies (F)

New York University Langone, Perlmutter Cancer Center, New York, NY.

Marc S Raab (MS)

University of Heidelberg, Baden-Württemberg, Germany.
German Cancer Research Center, Heidelberg, Germany.

Gareth Morgan (G)

New York University Langone, Perlmutter Cancer Center, New York, NY.

Niels Weinhold (N)

University of Heidelberg, Baden-Württemberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH